Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 33,925 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 33,925 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the sale, the director directly owned 1,223,579 shares in the company, valued at $73,891,935.81. This trade represents a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Establishment Labs Stock Down 2.4%

Shares of Establishment Labs stock opened at $58.16 on Wednesday. The business has a fifty day simple moving average of $69.47 and a 200 day simple moving average of $61.79. The stock has a market cap of $1.71 billion, a PE ratio of -33.43 and a beta of 0.91. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same quarter in the prior year, the firm earned ($1.19) earnings per share. The business’s quarterly revenue was up 45.2% on a year-over-year basis. Research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on ESTA. Mizuho lifted their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group upped their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. BTIG Research raised their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.86.

Institutional Trading of Establishment Labs

Large investors have recently made changes to their positions in the company. MV Capital Management Inc. acquired a new stake in Establishment Labs in the fourth quarter valued at $146,000. ADAR1 Capital Management LLC raised its position in shares of Establishment Labs by 89.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock worth $12,493,000 after acquiring an additional 80,734 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Establishment Labs in the fourth quarter worth approximately $3,421,000. SummitTX Capital L.P. bought a new stake in Establishment Labs in the fourth quarter valued at approximately $2,519,000. Finally, Tudor Investment Corp ET AL bought a new stake in Establishment Labs in the fourth quarter valued at approximately $12,852,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.